A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria - 18/04/17
Disclosure of potential conflict of interest: J. M. Harris, C. R. Cabanski, H. Scheerens, D. Samineni, M. S. Bradley, and C. Cochran are employees of Genentech, Inc, a member of the Roche group, and own Roche stock. P. Staubach has received study work from Genentech and has received personal fees from Novartis. M. Metz has received personal fees from Dr R. Pfleger, Moxie, Novartis, and UCB. G. Sussman has received a grant from Novartis; is an advisor and speaker for Novartis; and is an advisor for Merck, CSL Behring, and Pfizer. M. Maurer has received personal fees from Genentech, Novartis, Uriach, FAES, MOXIE, and Sanofi, and has received grants from Novartis, Uriach, FAES, and MOXIE. |
Vol 138 - N° 6
P. 1730-1732 - décembre 2016 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?